Cerenis Therapeutics is joining the Euronext indexes CAC® Small, CAC® Mid & Small and CAC® All- Tradable

Toulouse, FRANCE, Ann Arbor, UNITED STATES, September 17, 2015 – Cerenis Therapeutics (FR0012616852 - CEREN - Eligible PEA-PME), an international biopharmaceutical company dedicated to the discovery and development of innovative HDL therapies (“good cholesterol”) for treating cardiovascular and metabolic diseases, today announces its inclusion, as of September 21, 2015, in three new indexes from the Euronext CAC family: CAC® Small, CAC® Mid & Small and CAC® All- Tradable.

The inclusion of Cerenis shares in these indexes is the result of a share liquidity analysis made by Euronext on the basis of two criteria: amount of capital traded and free float market capitalization. The scope of the liquidity criteria highlights the marked interest from investors for Cerenis Therapeutics, despite the recent listing of the company, which has accomplished the first steps of its clinical development plan, as committed to within the framework of its initial public offering last March. Since then, the company has also strengthened its Board of Directors, and confirmed the proof of concept of its flagship product CER-001 and the optimal design of its clinical studies, thus demonstrating its potential for value creation in the short and medium term.

Cerenis shares are also included in the Next Biotech Index (QS0011095955 - BIOTK), a unique biotech index which helps investors and fund managers track the performance of European biotechnology stocks, an innovative sector with the fastest growth rate. As of today, the Index consists of 40 companies listed on the Euronext and Alternext exchanges.

About Cerenis Therapeutics: www.cerenis.com

Cerenis Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of innovative HDL therapies for the treatment of cardiovascular and metabolic diseases. HDL is the primary mediator of the reverse lipid transport, or RLT, the only natural pathway by which excess cholesterol is removed from arteries and is transported to the liver for elimination from the body.

Cerenis is developing a portfolio of HDL therapies, including HDL-mimetics for the rapid regression of atherosclerotic plaque in high-risk patients such as post-ACS patients and patients with HDL deficiency, and drugs which increase HDL for patients with low number of HDL particles to treat atherosclerosis and associated metabolic diseases.

Cerenis is well-positioned to become one of the leaders in the HDL therapeutic market, with a broad portfolio of programs being developed. Since its inception in 2005, the company has been funded by top tier investors: Sofinnova Partners, HealthCap, Alta Partners, EDF Ventures, Daiwa Corporate Investment, TVM Capital, Orbimed, IRDI/Ixo Private Equity and Bpifrance (Fund for Strategic Investment) and last March successfully completed an IPO on Euronext raising €53.4m.

About CER-001:

CER-001 is an engineered complex of recombinant human apoA-I, the major structural protein of HDL, and phospholipids. It has been designed to mimic the structure and functions of natural, nascent HDL, also known as pre-beta HDL. Its mechanism of action is to increase apoA-I and the number of HDL particles transiently, to stimulate the removal of excess cholesterol and other lipids from tissues including the arterial wall and to transport them to the liver for elimination through a process called Reverse Lipid Transport. Phase II studies have provided important data demonstrating the efficacy of CER-001 in regressing atherosclerosis in several distinct vascular beds in patients representing the entire spectrum of cholesterol homeostasis. The totality of the data to date indicates that CER-001 performs all of the functions of natural pre-beta HDL particles and has the potential to be the best-in-class HDL mimetic in the market.
Contacts:

Cerenis
Jean-Louis Dasseux
CEO
info@cerenis.com
Tel: +33 (0)5 62 24 09 49

NewCap
Investors relations
Emmanuel Huynh / Louis-Victor Delouvrier
cerenis@newcap.fr
Tel: +33 (0)1 44 71 98 53

NewCap
Media relations
Nicolas Merigeau
cerenis@newcap.fr
Tel: +33 (0)1 44 71 94 98